Affiliation:
1. Department of Health Sciences, Helsana Group, Zurich, Switzerland
2. Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland
3. Institute of Primary Care, University of Zurich and University Hospital Zurich, Zurich, Switzerland
Abstract
Background
In Europe and other high-income countries, antibiotics are mainly prescribed in the outpatient setting, which consists of primary, specialist and hospital-affiliated outpatient care. Established surveillance platforms report antimicrobial consumption (AMC) on aggregated levels and the contribution of the different prescriber groups is unknown.
Aim
To determine the contribution of different prescribers to the overall outpatient AMC in Switzerland.
Methods
We conducted a retrospective observational study using claims data from one large Swiss health insurance company, covering the period from 2015 to 2022. We analysed antibiotic prescriptions (ATC code J01) prescribed in the Swiss outpatient setting. Results were reported as defined daily doses per 1,000 inhabitants per day (DID) and weighted according to the total population of Switzerland based on census data.
Results
We analysed 3,663,590 antibiotic prescriptions from 49 prescriber groups. Overall, AMC ranged from 9.12 DID (2015) to 7.99 DID (2022). General internal medicine (40.1% of all prescribed DID in 2022), hospital-affiliated outpatient care (20.6%), group practices (17.3%), paediatrics (5.4%) and gynaecology (3.7%) were the largest prescriber groups. Primary care accounted for two-thirds of the prescribed DID. Quantity and type of antibiotics prescribed varied between the prescriber groups. Broad-spectrum penicillins, tetracyclines and macrolides were the most prescribed antibiotic classes.
Conclusion
Primary care contributed considerably less to AMC than anticipated, and hospital-affiliated outpatient care emerged as an important prescriber. Surveillance at the prescriber level enables the identification of prescribing patterns within all prescriber groups, offering unprecedented visibility and allowing a more targeted antibiotic stewardship according to prescriber groups.
Publisher
European Centre for Disease Control and Prevention (ECDC)
Reference34 articles.
1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.;Murray;Lancet,2022
2. World Health Organization (WHO). Global action plan on antimicrobial resistance. Geneva: WHO; 2015. Available from: https://www.who.int/publications/i/item/9789241509763
3. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.;Goossens;Lancet,2005
4. Federal Office of Public Health and Federal Food Safety and Veterinary Office. Swiss Antibiotic Resistance Report 2022. Usage of antibiotics and occurrence of antibiotic resistance in Switzerland. Bern: Federal Office of Public Health and Federal Food Safety and Veterinary Office; 2022. Available from: https://www.anresis.ch/publication-category/sarr
5. European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption in the EU/EEA (ESAC-Net) - Annual Epidemiological Report for 2022. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2022